A Guide To The Risks Of Investing In Day One Biopharmaceuticals Inc. (DAWN)

0
12

Day One Biopharmaceuticals Inc.’s filing revealed that its Director Grant Julie Papanek unloaded Company’s shares for reported $0.1 million on Nov 02. In the deal valued at $20.01 per share,5,000 shares were sold. As a result of this transaction, Grant Julie Papanek now holds 419,358 shares worth roughly $ 8.17 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, York Charles N II sold 10,000 shares, generating $200,313 in total proceeds. Upon selling the shares at $20.03, the COO, CFO and Secretary now owns 294,401 shares.

Before that, Grant Julie Papanek sold 5,000 shares. Day One Biopharmaceuticals Inc. shares valued at $100,208 were divested by the Director at a price of $20.04 per share. As a result of the transaction, Grant Julie Papanek now holds 424,358 shares, worth roughly $8.27 million.

Price Performance Review of DAWN

On Monday, Day One Biopharmaceuticals Inc. [NASDAQ:DAWN] saw its stock jump 1.19% to $19.48. On the same session, the stock had its day’s lowest price of $18.885, but rose to a high of $19.84. Over the last five days, the stock has lost -7.85%. Day One Biopharmaceuticals Inc. shares have risen nearly 15.61% since the year began. Nevertheless, the stocks have fallen -26.02% over the past one year. While a 52-week high of $28.35 was reached on 08/12/22, a 52-week low of $5.44 was recorded on 05/27/22. SMA at 50 days reached $20.90, while 200 days put it at $15.63. A total of 0.51 million shares were traded, compared to the trading of 0.73 million shares in the previous session.

Levels Of Support And Resistance For DAWN Stock

The 24-hour chart illustrates a support level at 18.96, which if violated will result in even more drops to 18.45. On the upside, there is a resistance level at 19.92. A further resistance level may holdings at 20.36. The Relative Strength Index (RSI) on the 14-day chart is 44.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.59, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.96%. Stochastics %K at 38.74% indicates the stock is a holding.

How much short interest is there in Day One Biopharmaceuticals Inc.?

A steep rise in short interest was recorded in Day One Biopharmaceuticals Inc. stocks on Jul 14, 2022, growing by 0.63 million shares to a total of 7.81 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 7.18 million shares. There was a rise of 8.07%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 19.84% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.8.

Day One Biopharmaceuticals Inc. [DAWN] – Who Are The Largest Shareholders?

In filings from RA Capital Management LP, it is revealed that the company now owns 7,040,622 shares, or roughly 9.58% of the outstanding DAWN shares. In other words, the investor’s shares have risen by 980,532 from its previous 13-F filing of 6060090.0. Additionally, Fidelity Management & Research Co increased 167.60% of its stake after which the total value it holdings stand at $136,008,527, while Deerfield Management Co. LP added 68.33% of its stake to hold $70.35 million in the firm. Over the last quarter, Adage Capital Management LP purchased 2,570,976 shares of Day One Biopharmaceuticals Inc., while The Vanguard Group, Inc. bought -352,849 shares. At present, Franklin Advisers, Inc. is holding 2,449,493 shares valued at $49.06 million. T. Rowe Price Associates, Inc. owned 2,041,344 shares of the company at the time of its most recent 13F filing, worth $40.89 million.

According to FactSet, Day One Biopharmaceuticals Inc.’s share price will average $36.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 94.81 percent from its previous closing price of $19.25. Analysts expect Day One Biopharmaceuticals Inc. stock to reach the higher price of $40.00, while the lowest price estimate is $32.00. However, 5 analysts have rated DAWN stock as a Buy in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here